Provided by Tiger Trade Technology Pte. Ltd.

AKESO

93.600
-1.450-1.53%
Volume:7.15M
Turnover:672.65M
Market Cap:86.21B
PE:-64.93
High:96.000
Open:95.050
Low:93.400
Close:95.050
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.46
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.442
ROE:-13.59%
ROA:-4.57%
PB:8.69
PE(LYR):-64.93
PS:21.37

Loading ...

Movement Alert|AKESO Falls 3.06% in Regular Trading, Trading at HK$97.9

Market Focus
·
Sep 07

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up

Deep News
·
Sep 06

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

Stock News
·
Sep 04

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Stock News
·
Sep 04

Movement Alert|AKESO Rises 5.73% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint Versus Keytruda

Market Focus
·
Sep 04

Akeso Reports Stable Share Capital in August 2026; Minor Decline in Outstanding Options

Bulletin Express
·
Sep 03

Movement Alert|AKESO Rises 5.3% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint

Market Focus
·
Sep 03

Akeso: Ivonescimab Shows Significant Overall-Survival Gain Versus Pembrolizumab in Phase III HARMONI-2 Trial

Bulletin Express
·
Sep 03

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS
·
Sep 03

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Reuters
·
Sep 03

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS
·
Sep 03

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS
·
Sep 03

Movement Alert|AKESO Falls 3.06% in Regular Trading, Interim Earnings Miss and Bispecific Antibody Controversy Continue to Weigh

Market Focus
·
Sep 01

Movement Alert|AKESO Falls 3.15% in Regular Trading, H1 Earnings Miss Expectations Amid Ongoing Bispecific Antibody Concerns

Market Focus
·
Aug 31

Akeso, Inc. (HKG:9926) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.
·
Aug 31

Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint

Reuters
·
Aug 28

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

Movement Alert|AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth

Market Focus
·
Aug 28

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live
·
Aug 28